Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) yesterday and set a price ...

Q3 2024 Earnings Call Transcript November 8, 2024 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Q3 2024 Earnings Call Transcript November 7, 2024 The Trade Desk, Inc. beats earnings expectations. Reported EPS is $0.41, expectations were $0.3949. Operator: Greetings. Welcome to The Trade Desk ...

A recent report warns that if Canadian businesses don't accelerate generative AI adoption, they risk falling behind. Will the ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The ...

and VECTOR plasma-enhanced CVD ALD products. Receive News & Ratings for Lam Research Daily - Enter your email address below ...

But one billionaire investor in particular may have a different view when it comes to Palantir. In the second quarter, while Philippe Laffont of Coatue Management increased his holding of Nvidia, he ...

International Assets Investment Management LLC raised its stake in Vector Group Ltd. (NYSE:VGR – Free Report) by 2,284.9% ...